Adiuvant huaier on long-term survivals after curative hepatectomy for primary liver cancer
10.3760/cma.j.issn.1007-8118.2012.02.006
- VernacularTitle:槐耳颗粒对原发性肝癌患者术后长期生存的影响
- Author:
Tao YAN
;
Xinyu BI
;
Yi FANG
;
Jianguo ZHOU
;
Jianjun ZHAO
;
Zhen HUANG
;
Haitao ZHOU
;
Cong LI
;
Yuan LI
;
Ping ZHAO
;
Jianqiang CAI
- Publication Type:Journal Article
- Keywords:
Primary liver cancer;
Huaier;
Recurrence;
Metastasis
- From:
Chinese Journal of Hepatobiliary Surgery
2012;18(2):99-102
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of adjuvant Huaier on long-term survivals after curative partial hepatectomy for primary liver cancer.Methods 175 patients with primary liver cancer who received curative partial hepatectomy from January 2002 to January 2006 were divided into two groups:the treatment group (group A,n =87) and the control group (group B,n=88).Group A was treated with Huaier (60 g per day for 6 months) after the operation while group B received no Huaier treatment.Results The overall 1-,3- and 5 year survival rates and disease-free survival rates were 91.90％,73.90％,and 56.0％ and 68.1％,48.4％ and 40.2％,respectively.The overall 1-,3-and 5-year survival rates in group A were significantly higher than group B (91.80％,79.30％,65.2％ vs 92.0％,68.3％,46.6％,P 0.038).In addition,the 1-,3-and 5-year survival rates after tumor recurrence in group A was also significantly higher than group B (78.6％,46.9％,38.2％ vs 69.0％,16.8％,12.6％,P=0.040).Multivariate analysis showed that the use of Huaier,hepatitis infection,severity of cirrhosis,vascular cancer thrombus were the most important prognostic factors for overall long-term survival (P＜0.05).Blood transfusion and histological grade were independent risk factors for disease free survival.The use of Huaier and the clinicopathological type were significantly co-related to the survival from recurrence/metastasis to death.Conclusion The use of Huaier improved disease free survival and the survival from recurrence or metastasis for patients with primary liver cancer following curative hepatectomy.
